Study finds it generally safe to withdraw anti-seizure medication in children with epilepsy
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) is continuing with its review of the regulatory application for use of Byetta (exenatide) injection as stand-alone therapy (monotherapy) in people with type 2 diabetes who are not achieving acceptable blood sugar control. It is likely that this
Full Post: Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission
A new Mayo Clinic study found that it is generally safe to withdraw anti-seizure medications in children with epilepsy who have achieved seizure-freedom while on the medication.
Researchers found that these children were not at high risk of subsequently developing intractable epilepsy. The study will be presented on Sunday, Dec. 7, at the American Epilepsy Society’s annual meeting in Seattle.
Epilepsy is a disorder characterized by the occurrence of two or more seizures. It affects more than 3 million Americans. Approximately 10 percent of affected children have intractable epilepsy, a condition in which medications alone do not control seizures and seizures have a disabling effect on quality of life.
“It is often recommended that children with epilepsy who become seizure-free on anti-seizure medications be withdrawn from the drugs to avoid side effects of long-term use. Those potential side effects include cognitive slowing, incoordination, weight change, behavioral decline, and liver damage,” says Katherine Nickels, M.D., a Mayo Clinic pediatric neurologist and an author of this study. “However, few previous studies had examined the risk of intractable epilepsy following withdrawal of anti-seizure medication, and the reported risks varied widely.”
Dr. Nickels and a team of Mayo Clinic researchers set out to determine the frequency of intractable epilepsy in children who withdrew from anti-seizure medication after a period of seizure-freedom. The team reviewed the records of 241 children, ages 1 month to 16 years, who were diagnosed with new-onset epilepsy between 1990 and 2000. They identified 152 children who were diagnosed and treated with anti-seizure medication and had at least five years of follow-up. Of those, 56 children (37 percent) achieved seizure-freedom and were withdrawn from the medication. After an average follow-up of eight years, 20 children (36 percent) experienced at least one seizure recurrence. Fifteen of these children re-started the anti-seizure medication, and eight (53 percent) achieved seizure-freedom within one year, two (13 percent) achieved seizure-freedom after two years and only three (20 percent) developed intractable epilepsy. Overall, only 5 percent of the 56 children who withdrew from anti-seizure medication following seizure-freedom developed intractable epilepsy.
“The risk of children developing intractable epilepsy after withdrawal of anti-seizure medication was only 5 percent, which is similar to the risk of intractable epilepsy at the time of initial diagnosis of epilepsy in children,” says Dr. Nickels. “Therefore, the children who achieve seizure-freedom on anti-seizure medication should be considered for withdrawal without high risk of intractable epilepsy.”
Many people who suffer with epilepsy take a drug called Neurontin to control seizures, enabling them to live healthy active lives. Epilepsy is not a psychological disorder. It is a physical abnormality in the brain involving neurons that clash with other neurons. This can cause convulsions and even unconsciousness. During a convulsion (or seizure), the neurons
Full Post: Neurontin for treating epilepsy
Two children have a seizure. One child never has another seizure. Twenty years later, the other child has a series of seizures and is diagnosed with epilepsy. A study being led by researchers at Rensselaer Polytechnic Institute is looking at what could possibly happen in the development of these two children that would lead
Full Post: New understanding of seizure behaviors and epilepsy
Persons with temporal lobe epilepsy who do not respond to medication could receive a substantial gain in life expectancy and quality of life by undergoing surgery of the temporal lobe part of the brain, according to an analysis reported in the December 3 issue of JAMA, the Journal of the American Medical Association. Despite currently
Full Post: Analysis supports use of temporal lobe resection to treat medication-resistant epilepsy
Early diagnosis and treatment that quickly achieves seizure freedom with nominal side effects is the key goal to epilepsy management. Three studies highlighted at the AES annual meeting address this goal from different vantage points: The course to seizure freedom? Identifying factors that may change the landscape of epilepsy treatment to improve patients’
Full Post: New research reports on interventions that may alter the course of epilepsy diagnosis and management
New therapies for some forms of epilepsy may soon be possible, thanks to a discovery made by a team of University of British Columbia and Vancouver Coastal Health Research Institute neuroscience researchers. The researchers found that hemichannels - the same channels the researchers previously found to that cause cell death following a stroke - may
Full Post: Hemichannels - new target to treat epileptic seizures following brain trauma or stroke